J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of

Attorney General Keith Ellison announced a settlement with Novo Nordisk that let's Minnesotans buy its insulin products for $35 per month.

ST. PAUL, Minn. – All Minnesotans, whether they have insurance or not, will be able to buy insulin products for $35 a month for the next five years.

Novo Nordisk has agreed to cap insulin prices at $35, settling a lawsuit from Minnesota's Attorney General over allegations of inflated drug prices. The settlement, lasting five years, also provides free insulin to the neediest.

Now Novo Nordisk is required to provide insulin products at $35 per monthly prescription for customers paying with cash. The settlement also requires all three companies to use a texting system to raise awareness of low-cost insulin options, according to the press release.

Novo Nordisk has agreed to a legal settlement capping insulin prices, following Minnesota's attorney general's accusations of price gouging. The settlement mandates a price cap of $35 per monthly prescription and provides free insulin to needy Minnesotans.

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.